Semi-classical analysis of non self-adjoint transfer matrices in statistical mechanics. I

We propose a way to study one-dimensional statistical mechanics models with complex-valued action using transfer operators. The argument consists of two steps. First, the contour of integration is deformed so that the associated transfer operator is a perturbation of a normal one. Then the transfer operator is studied using methods of semi-classical analysis. In this paper we concentrate on the second step, the main technical result being a semi-classical estimate for powers of an integral operator which is approximately normal.Comment: 28 pp, improved the presentatio

Inverting Ray-Knight identity

We provide a short proof of the Ray-Knight second generalized Theorem, using a martingale which can be seen (on the positive quadrant) as the Radon-Nikodym derivative of the reversed vertex-reinforced jump process measure with respect to the Markov jump process with the same conductances. Next we show that a variant of this process provides an inversion of that Ray-Knight identity. We give a similar result for the Ray-Knight first generalized Theorem.Comment: 18 page

Topological Graph Polynomials in Colored Group Field Theory

In this paper we analyze the open Feynman graphs of the Colored Group Field Theory introduced in [arXiv:0907.2582]. We define the boundary graph \cG_{\partial} of an open graph \cG and prove it is a cellular complex. Using this structure we generalize the topological (Bollobas-Riordan) Tutte polynomials associated to (ribbon) graphs to topological polynomials adapted to Colored Group Field Theory graphs in arbitrary dimension

Functional Integral Construction of the Thirring model: axioms verification and massless limit

We construct a QFT for the Thirring model for any value of the mass in a functional integral approach, by proving that a set of Grassmann integrals converges, as the cutoffs are removed and for a proper choice of the bare parameters, to a set of Schwinger functions verifying the Osterwalder-Schrader axioms. The corresponding Ward Identities have anomalies which are not linear in the coupling and which violate the anomaly non-renormalization property. Additional anomalies are present in the closed equation for the interacting propagator, obtained by combining a Schwinger-Dyson equation with Ward Identities.Comment: 55 pages, 9 figure

On Batalin-Vilkovisky Formalism of Non-Commutative Field Theories

We apply the BV formalism to non-commutative field theories, introduce BRST symmetry, and gauge-fix the models. Interestingly, we find that treating the full gauge symmetry in non-commutative models can lead to reducible gauge algebras. As one example we apply the formalism to the Connes-Lott two-point model. Finally, we offer a derivation of a superversion of the Harish-Chandra-Itzykson-Zuber integral.Comment: 20 pages, LaTeX. v2: minor corrections. v3: Added an Appendix about Harish-Chandra-Itzykson-Zuber integrals. v4: Added Reference

Constructive Field Theory and Applications: Perspectives and Open Problems

In this paper we review many interesting open problems in mathematical physics which may be attacked with the help of tools from constructive field theory. They could give work for future mathematical physicists trained with the constructive methods well within the 21st century

Cluster and virial expansions for the multi-species tonks gas

We consider a mixture of non-overlapping rods of different lengths ℓk moving in R or Z. Our main result are necessary and sufficient convergence criteria for the expansion of the pressure in terms of the activities zk and the densities ρk. This provides an explicit example against which to test known cluster expansion criteria, and illustrates that for non-negative interactions, the virial expansion can converge in a domain much larger than the activity expansion. In addition, we give explicit formulas that generalize the well-known relation between non-overlapping rods and labelled rooted trees. We also prove that for certain choices of the activities, the system can undergo a condensation transition akin to that of the zero-range process. The key tool is a fixed point equation for the pressure

Quantum Gravity, Field Theory and Signatures of Noncommutative Spacetime

A pedagogical introduction to some of the main ideas and results of field theories on quantized spacetimes is presented, with emphasis on what such field theories may teach us about the problem of quantizing gravity. We examine to what extent noncommutative gauge theories may be regarded as gauge theories of gravity. UV/IR mixing is explained in detail and we describe its relations to renormalization, to gravitational dynamics, and to deformed dispersion relations in models of quantum spacetime of interest in string theory and in doubly special relativity. We also discuss some potential experimental probes of spacetime noncommutativity.Comment: 26 pages, 4 figures; v2: comments and references added; v3: typos corrected, clarifying comments and references added; Based on Plenary Lecture delivered at the XXIX Encontro Nacional de Fisica de Particulas e Campos, Sao Lourenco, Brasil, September 22-26, 2008; Final version to be published in General Relativity and Gravitatio

Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry

AimsTo analyse the effectiveness of cardiac resynchronization therapy (CRT) in patients with valvular heart disease (a subset not specifically investigated in randomized controlled trials) in comparison with ischaemic heart disease or dilated cardiomyopathy patients.Methods and resultsPatients enrolled in a national registry were evaluated during a median follow-up of 16 months after CRT implant. Patients with valvular heart disease treated with CRT (n = 108) in comparison with ischaemic heart disease (n = 737) and dilated cardiomyopathy (n = 635) patients presented: (i) a higher prevalence of chronic atrial fibrillation, with atrioventricular node ablation performed in around half of the cases; (ii) a similar clinical and echocardiographic profile at baseline; (iii) a similar improvement of LVEF and a similar reduction in ventricular volumes at 6-12 months; (iv) a favourable clinical response at 12 months with an improvement of the clinical composite score similar to that occurring in patients with dilated cardiomyopathy and more pronounced than that observed in patients with ischaemic heart disease; (v) a long-term outcome, in term of freedom from death or heart transplantation, similar to patients affected by ischaemic heart disease and basically more severe than that of patients affected by dilated cardiomyopathy.ConclusionIn 'real world' clinical practice, CRT appears to be effective also in patients with valvular heart disease. However, in this group of patients the outcome after CRT does not precisely overlap any of the two other groups of patients, for which much more data are currently available

Valsartan for prevention of recurrent atrial fibrillation

BACKGROUND: Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation. METHODS: We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had to have underlying cardiovascular disease, diabetes, or left atrial enlargement. Patients were randomly assigned to receive valsartan or placebo. The two primary end points were the time to a first recurrence of atrial fibrillation and the proportion of patients who had more than one recurrence of atrial fibrillation over the course of 1 year. RESULTS: A total of 1442 patients were enrolled in the study. Atrial fibrillation recurred in 371 of the 722 patients (51.4%) in the valsartan group, as compared with 375 of 720 (52.1%) in the placebo group (adjusted hazard ratio, 0.97; 96% confidence interval [CI], 0.83 to 1.14; P = 0.73). More than one episode of atrial fibrillation occurred in 194 of 722 patients (26.9%) in the valsartan group and in 201 of 720 (27.9%) in the placebo group (adjusted odds ratio, 0.89; 99% CI, 0.64 to 1.23; P = 0.34). The results were similar in all predefined subgroups of patients, including those who were not receiving angiotensin-converting-enzyme inhibitors. CONCLUSIONS: Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation